Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met.

The American journal of pathology - 1 Jan 2004

Takaoka Yutaka, Ohta Mika, Miyakawa Kazuhisa, Nakamura Osamu, Suzuki Misao, Takahashi Kiyoshi, Yamamura Ken-Ichi, Sakaki Yoshiyuki

Abstract excerpt

Type I familial amyloidotic polyneuropathy (FAP), a systemic amyloidosis, is characterized by aggregation of variant transthyretin (TTR Val30Met) into stable, insoluble fibrils. This aggregation is caused by genetic and environmental factors. Genetic factors have been studied extensively. However, little is known about environmental or physiological factors involved in the disease process, and their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis, Familial
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cysteine

Share to Immunoblotting

Share to Mice, Transgenic

Share to Prealbumin

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Transgenes

Source

Open in PubMed Open full text

Identifiers

PMID: 14695346
DOI: 10.1016/s0002-9440(10)63123-9
PMCID: PMC1602210

Genes

TTR
FAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met.PMID 14695346Read ↗

Transthyretin mutagenesis: impact on amyloidogenesis and disease.Semantic proximity Read ↗

Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?Semantic proximity Read ↗

Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation.Semantic proximity Read ↗

Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.Semantic proximity Read ↗

The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells.Semantic proximity Read ↗

Genetic and structural aspects of amyloid diseases.Semantic proximity Read ↗

Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in JapanSemantic proximity Read ↗

Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.Semantic proximity Read ↗

Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy.Semantic proximity Read ↗

The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.Semantic proximity Read ↗

A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.Semantic proximity Read ↗

Different disease-causing mutations in transthyretin trigger the same conformational conversion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.